Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760097 · ClinicalTrials.gov registry record · Phase 4
Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression
A Phase 4 study of Depression, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00760097 is a Phase 4 study of Depression that has completed, run by University of California, Los Angeles. The registered enrollment target is 18 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00760097, a Phase 4 study of Depression, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
People who have depression often have symptoms besides sad mood. Cognitive symptoms, such as poor memory, concentration, and decision making, are associated with disability in many spheres of life, and these symptoms often persist even when antidepressant treatment improves other symptoms (mood, energy, sleep, anxiety). Antidepressants alone fail to produce full remission for many patients, so it is important to study adjunctive treatments which can be added onto medication treatment and help restore cognitive function. The method of transcranial direct current stimulation (tDCS) has been shown by others to improve working memory and cognitive functions, and also to help with other symptoms of depression. tDCS involves passing a small, constant current between saline-moistened pads placed on the scalp. In this proposed study, 20 individuals with major depression who have cognitive difficulties despite taking antidepressants will participate. Over the course of a two-week period, each person will receive 5 sessions of either active tDCS or inactive treatments, in addition to their medication. Each session lasts for 20 minutes, and will be administered on alternating days (M-W-F). Assessments of depressive symptoms, cognitive function, and brain activity will be made prior to any sessions, after the first one, and after the fifth (final) session; brain function will be assessed by measuring the brain's electrical activity ("brain waves").
Conditions Studied
Interventions
- DEVICE Transcranial direct stimulation
Study Locations (1)
California
- UCLA Semel Institute for Neuroscience - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760097
The ClinicalTrials.gov registry entry for NCT00760097 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Transcranial direct stimulation is the first listed.
NCT00760097 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00760097 about?
NCT00760097 is a clinical study titled "Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression". People who have depression often have symptoms besides sad mood. Cognitive symptoms, such as poor memory, concentration, and decision making, are associated with disability in many spheres of life, and these symptoms often persist even when antidepressant treatment improves other symptoms (mood, ene...
What is the current status of trial NCT00760097?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2007-09. Estimated completion is 2009-05.
What conditions does trial NCT00760097 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00760097?
The interventions under investigation include: Transcranial direct stimulation (DEVICE).
Who is sponsoring clinical trial NCT00760097?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00760097 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.